Drug intelligence / Profile preview

Lu AF87908

Development stage: Phase 1
Lead developer: Lundbeck
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Lu AF87908 is a humanized IgG1 monoclonal antibody developed by Lundbeck for the treatment of Alzheimer's disease. It specifically targets phosphorylated tau protein at the serine 396 site, acting as a tau inhibitor. The drug is designed to bind and inhibit microtubule-associated protein tau (MAPT), which plays a key role in the pathogenesis of Alzheimer's disease and other tauopathies. Its mechanism aims to reduce pathological tau aggregation and spread within the brain, potentially modifying disease progression[1][2][8].

Other names: Lu-AF87908Lu-AF-87908Lu-AF 87908

Targets

aggregated p-tau (Microtubule-associated protein tau (aggregated/paired helical filament form))

Beyond the preview

Go deeper on Lu AF87908.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lu AF87908.

Explore the full profile